Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

Critical Path Institute® (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington ...

Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...